WALLWST.sNUMBERSN

Home
Stocks
CHRO
Cash from investing

Chromocell Therapeutics (CHRO) Cash From Investing

General

Overview

Market data

Price
Market cap
Shares outstanding
Beta
Moving average
RSI
Volatility
ATR

Dividend

Dividend per share
Dividend yield
Payout ratio
Dividends paid

Profitability

Revenue
Gross profit
Gross margin
Operating profit
Operating margin
Net income
Net margin
EPS
EBIT
EBITDA
ROA
ROE

Valuation

PE ratio
PB ratio
PS ratio
EV/EBITDA
Enterprise value

Financial Health

Debt to equity
Current ratio
Quick ratio
Interest coverage ratio
Piotroski F-Score
Altman Z-Score

Equity

Shareholders equity
Book value
Retained earnings
Working capital

Assets

Total assets
Current assets
Non current assets
Cash and cash equivalents
Accounts receivable
Inventory

Liabilities

Total liabilities
Current liabilities
Long term liabilities
Accounts payable
Total debt
Short term debt
Long term debt

Expenses

Total expenses
Operating expenses
Cost of goods sold
Selling, general & administrative expenses
Depreciation and amortization
Interest expense
Income tax

Cash Flow

Cash from operations
Cash from investing
Cash from financing
CAPEX
Free cash flow

Other

Financials

There is no historical data available for Chromocell Therapeutics Cash From Investing

Premium FAQ Terms and conditions Privacy policy Sitemap Contact us

© 2025 WallStreetNumbers